A085660 Stock Overview
CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CHA Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,410.00 |
| 52 Week High | ₩18,250.00 |
| 52 Week Low | ₩11,930.00 |
| Beta | 0.53 |
| 1 Month Change | 16.48% |
| 3 Month Change | 8.75% |
| 1 Year Change | -14.15% |
| 3 Year Change | -31.21% |
| 5 Year Change | -18.03% |
| Change since IPO | 106.47% |
Recent News & Updates
Shareholder Returns
| A085660 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | 3.4% | 3.9% | 1.8% |
| 1Y | -14.2% | 16.9% | -2.3% |
Return vs Industry: A085660 underperformed the KR Healthcare industry which returned 16.9% over the past year.
Return vs Market: A085660 underperformed the KR Market which returned -2.5% over the past year.
Price Volatility
| A085660 volatility | |
|---|---|
| A085660 Average Weekly Movement | 4.6% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 12.3% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A085660 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: A085660's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 266 | Hoon Oh Sang | https://www.chabio.com |
CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services. The company operates a cord blood consignment storage business for the treatment of intractable diseases, as well as provides regenerative medicines, Immune and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs comprising fitness, spa, and supplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It also offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.
CHA Biotech Co., Ltd. Fundamentals Summary
| A085660 fundamental statistics | |
|---|---|
| Market Cap | ₩845.68b |
| Earnings (TTM) | -₩37.04b |
| Revenue (TTM) | ₩892.98b |
0.9x
P/S Ratio-22.8x
P/E RatioIs A085660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A085660 income statement (TTM) | |
|---|---|
| Revenue | ₩892.98b |
| Cost of Revenue | ₩666.25b |
| Gross Profit | ₩226.73b |
| Other Expenses | ₩263.77b |
| Earnings | -₩37.04b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -674.89 |
| Gross Margin | 25.39% |
| Net Profit Margin | -4.15% |
| Debt/Equity Ratio | 59.9% |
How did A085660 perform over the long term?
See historical performance and comparison